1. Home
  2. IRD vs ORIS Comparison

IRD vs ORIS Comparison

Compare IRD & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • ORIS
  • Stock Information
  • Founded
  • IRD 2018
  • ORIS 2014
  • Country
  • IRD United States
  • ORIS China
  • Employees
  • IRD N/A
  • ORIS N/A
  • Industry
  • IRD
  • ORIS Farming/Seeds/Milling
  • Sector
  • IRD
  • ORIS Consumer Staples
  • Exchange
  • IRD NYSE
  • ORIS Nasdaq
  • Market Cap
  • IRD 36.1M
  • ORIS 30.4M
  • IPO Year
  • IRD N/A
  • ORIS 2024
  • Fundamental
  • Price
  • IRD $1.15
  • ORIS $1.14
  • Analyst Decision
  • IRD Strong Buy
  • ORIS
  • Analyst Count
  • IRD 1
  • ORIS 0
  • Target Price
  • IRD $8.00
  • ORIS N/A
  • AVG Volume (30 Days)
  • IRD 154.1K
  • ORIS 321.3K
  • Earning Date
  • IRD 02-19-2025
  • ORIS 02-21-2025
  • Dividend Yield
  • IRD N/A
  • ORIS N/A
  • EPS Growth
  • IRD N/A
  • ORIS N/A
  • EPS
  • IRD N/A
  • ORIS 0.43
  • Revenue
  • IRD $8,381,000.00
  • ORIS $16,745,999.00
  • Revenue This Year
  • IRD N/A
  • ORIS N/A
  • Revenue Next Year
  • IRD $29.37
  • ORIS N/A
  • P/E Ratio
  • IRD N/A
  • ORIS $2.65
  • Revenue Growth
  • IRD N/A
  • ORIS N/A
  • 52 Week Low
  • IRD $0.81
  • ORIS $1.12
  • 52 Week High
  • IRD $2.77
  • ORIS $21.24
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • ORIS N/A
  • Support Level
  • IRD N/A
  • ORIS N/A
  • Resistance Level
  • IRD N/A
  • ORIS N/A
  • Average True Range (ATR)
  • IRD 0.00
  • ORIS 0.00
  • MACD
  • IRD 0.00
  • ORIS 0.00
  • Stochastic Oscillator
  • IRD 0.00
  • ORIS 0.00

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About ORIS Oriental Rise Holdings Limited Ordinary Shares

Oriental Rise Holdings Ltd is a company who is an integrated supplier of tea products in Mainland China. Their major tea products include primarily-processed tea consisting of white tea and black tea, and refined white tea and black tea. Its business operations are vertically integrated, covering cultivation, processing of tea leaves and the sale of tea products to tea business operators (such as wholesale distributors) and end-user retail customers in Mainland China.

Share on Social Networks: